Accelerated hematopoietic recovery with angiotensin-(1-7) after total body radiation

Int J Radiat Biol. 2012 Jun;88(6):466-76. doi: 10.3109/09553002.2012.676228. Epub 2012 Apr 30.


Purpose: Angiotensin (1-7) [A(1-7)] is a component of the renin angiotensin system (RAS) that stimulates hematopoietic recovery after myelosuppression. In a Phase I/IIa clinical trial, thrombocytopenia after chemotherapy was reduced by A(1-7). In this study, the ability of A(1-7) to improve recovery after total body irradiation (TBI) is shown with specific attention to radiation-induced hematopoietic injury.

Materials and methods: Mice were exposed to TBI (doses of 2-7 Gray [Gy]) of cesium 137 gamma rays, followed by treatment with A(1-7), typical doses were 100-1000 μg/kg given once or once daily for a specified number of days depending on the study. Animals are injected subcutaneously via the nape of the neck with 0.1 ml drug in saline. The recovery of blood and bone marrow cells was determined. Effects of TBI and A(1-7) on survival and bleeding time was also evaluated.

Results: Daily administration of A(1-7) after radiation exposure improved survival (from 60% to 92-97%) and reduced bleeding time at day 30 after TBI. Further, A(1-7) increased early mixed progenitors (3- to 5-fold), megakaryocyte (2- to 3-fold), myeloid (3- to 6-fold) and erythroid (2- to 5-fold) progenitors in the bone marrow and reduced radiation-induced thrombocytopenia (RIT) (up to 2-fold). Reduction in the number of treatments to 3 per week also improved bone marrow recovery and reduced RIT. As emergency responder and healthcare systems in case of nuclear accident or/and terrorist attack may be overwhelmed, the consequence of delayed initiation of treatment was ascertained. Treatment with A(1-7) can be delayed up to 5 days and still be effective in the reduction of RIT or acceleration of bone marrow recovery.

Conclusions: The data presented in this paper indicate that A(1-7) reduces the consequences of critical radiation exposure and can be initiated well after initial exposure with maximal effects on early responding hematopoietic progenitors when treatment is initiated 2 days after exposure and 5 days after exposure for the later responding progenitors and reduced thrombocytopenia. There was some effect of A(1-7) even when given days after radiation exposure.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Anemia / etiology
  • Anemia / prevention & control
  • Angiotensin I / administration & dosage
  • Angiotensin I / pharmacology*
  • Animals
  • Dose-Response Relationship, Drug
  • Dose-Response Relationship, Radiation
  • Drug Administration Schedule
  • Female
  • Hematopoiesis / drug effects*
  • Hematopoiesis / physiology
  • Hematopoiesis / radiation effects*
  • Hematopoietic Stem Cells / cytology
  • Hematopoietic Stem Cells / drug effects
  • Hematopoietic Stem Cells / radiation effects
  • Leukopenia / etiology
  • Leukopenia / prevention & control
  • Mice
  • Mice, Inbred C57BL
  • Peptide Fragments / administration & dosage
  • Peptide Fragments / pharmacology*
  • Radiation-Protective Agents / administration & dosage
  • Radiation-Protective Agents / pharmacology
  • Renin-Angiotensin System / physiology
  • Thrombocytopenia / etiology
  • Thrombocytopenia / prevention & control
  • Whole-Body Irradiation* / adverse effects


  • Peptide Fragments
  • Radiation-Protective Agents
  • Angiotensin I
  • angiotensin I (1-7)